GUANFACINE HYDROCHLORIDE (guanfacine hydrochloride) by Teva is adrenergic alpha2-agonists [moa]. Approved for the management of hypertension, hypertension. First approved in 2021.
Drug data last refreshed 22h ago
Adrenergic alpha2-Agonists
Central alpha-2 Adrenergic Agonist
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
Worked on GUANFACINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.